Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo

7 Mar 2022

Abstract excerpt

Yellow fever virus (YFV) infection is a major public concern that threatens a large population in South America and Africa. No specific anti-YFV drugs are available till now. Here, we report that rifapentine is a potent YFV inhibitor in various cell lines by high-throughput drugs screening, acting at both cell entry and replication steps. Kinetic test and binding assay suggest that rifapentine interferes the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Mosquito-borne diseases and control
Share to Viral Infections and Vectors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35249454
DOI: 10.1080/22221751.2022.2049983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivoPMID 35249454Read ↗

Identification of Inhibitors of Yellow Fever Virus Replication Using a Replicon-Based High-Throughput AssaySemantic proximity Read ↗

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesSemantic proximity Read ↗

Alphavirus antivirals targeting RNA‐dependent RNA polymerase domain of nsP4 divulged using surface plasmon resonanceSemantic proximity Read ↗

Identification of West Nile virus RNA-dependent RNA polymerase non-nucleoside inhibitors by real-time high throughput fluorescence screeningSemantic proximity Read ↗

Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymeraseSemantic proximity Read ↗

Q63, a novel DENV2 RdRp non-nucleoside inhibitor, inhibited DENV2 replication and infectionSemantic proximity Read ↗

Insights into RNA-dependent RNA Polymerase Inhibitors as Antiinfluenza Virus AgentsSemantic proximity Read ↗

Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance ProfilingSemantic proximity Read ↗

RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3XSemantic proximity Read ↗

RdRp inhibitors and COVID-19: Is molnupiravir a good option?Semantic proximity Read ↗

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drugSemantic proximity Read ↗

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design ChallengeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.